----

----

| x      | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934     |
|--------|------------------------------------------------------------------------------------------|
|   |                                                                                     |
|   | For the fiscal year ended October 31, 2011                                               |
|   |                                                                                     |
|   | OR                                                                                       |
|   |                                                                                     |
|  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |

----

|   | Large accelerated filer |  ̈ |   | Accelerated filer         |  ̈ |
|--------|-------------------------|--------|--------|---------------------------|--------|
|   |                    |   |   |                      |   |
|   | Non-accelerated filer   |  ̈ |   | Smaller reporting company | x      |

----

----

|                                              |                                                                                                               |   | Page   |   |
|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
| Special Note Regarding Forward Looking Statements |                                                                                                               |   | 4      |   |
| PART I                                            |                                                                                                               |   |   |   |   |
| Item 1.                                           | Business                                                                                                           |   |   | 5      |   |
| Item 1A.                                          | Risk Factors                                                                                                       |   |   | 15     |   |
| Item 1B.                                          | Unresolved Staff Comments                                                                                          |   |   | 16     |   |
| Item 2.                                           | Properties                                                                                                         |   |   | 16     |   |
| Item 3.                                           | Legal Proceedings                                                                                                  |   |   | 16     |   |
| Item 4.                                           | (Removed and Reserved)                                                                                             |   |   | 16     |   |
|                                              |                                                                                                               |   |   |   |   |
| PART II                                           |                                                                                                               |   |   |   |   |
| Item 5.                                           | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |   |   | 16     |   |
| Item 6.                                           | Selected Financial Data                                                                                            |   |   | 17     |   |
| Item 7.                                           | Management’s Discussion and Analysis of Financial Condition and Results of Operations                        |   |   | 18     |   |
| Item 7A.                                          | Quantitative and Qualitative Disclosures about Market Risk                                                         |   |   | 30     |   |
| Item 8.                                           | Financial Statements and Supplementary Data                                                                        |   |   |   |   |
| Item 9.                                           | Changes In and Disagreements With Accountants on Accounting and Financial Disclosure                               |   |   | 29     |   |
| Item 9A.                                          | Controls and Procedures                                                                                            |   |   | 29     |   |
| Item 9B.                                          | Other Information                                                                                                  |   |   | 30     |   |
|                                              |                                                                                                               |   |   |   |   |
| PART III                                          |                                                                                                               |   |   |   |   |
| Item 10.                                          | Directors, Executive Officers and Corporate Governance                                                             |   |   | 30     |   |
| Item 11.                                          | Executive Compensation                                                                                             |   |   | 34     |   |
| Item 12.                                          | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                     |   |   | 35     |   |
| Item 13.                                          | Certain Relationships and Related Transactions, and Director Independence                                          |   |   | 36     |   |
| Item 14.                                          | Principal Accounting Fees and Services                                                                             |   |   | 36     |   |
| Item 15.                                          | Exhibits, Financial Statement Schedules                                                                            |   |   | 38     |   |

----

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

----

ITEM 1. BUSINESS

----

----

----

| 1. | Increased mechanical strength to 170Mpa                                                                                                   |
|----|-------------------------------------------------------------------------------------------------------------------------------------------|
| 2. | Increased biological activities to accelerate bone cell substitution.                                                                     |
| 3. | Extended the degeneration period during the implant. While the PA is degenerating layer by layer, the bone cells grow and take its place. |

----

| 1.     | Our Company is researching and currently developing the capability of manufacturing several different kinds of human implant products including Artificial Lumber Disc, Mini-Screws, Suture Anchors, reconstructive dental devices and other PA products. Currently the company has two production lines certified by the GMP regulations. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                       |
| 2.     | Our Company is constantly analyzing the market needs to develop suitable products. One of the company’s products is currently pending SFDA approval and two products are under clinical tests.                                                                                                                                       |

----

|   | - patients                                |
|--------|-------------------------------------------|
|   | - advanced technology level               |
|   | - performance and price of the materials. |

|   | · | There are no similar patent registrations in China.                                                                                                                                              |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | · | Our initial product, the PA Screw, has completed 100% of the required clinical trials, with a 100% success rate, and now await the formality of SFDA approval.                              |
|   | · | We are the only company qualified and permitted to conduct clinical trials of other PA products by China’s SFDA.                                                                           |
|   | · | We have a timing advantage over other companies in China, which would have to go through the preclinical testing before they could even apply for a permit to conduct actual clinical trials.    |
|   | · | Under existing regulation structure, it will take at least 3 years for any competitor’s clinical trials to be completed, and total of 7 or more years to reach the point where we are now. |

----

| Competing products and prices in China (screw) |
|------------------------------------------------|
| Producer                                       | Origin | Brand | Price (USD/PC) |
| Arthrex                                        | Germany/USA | Arthrex | $554.74 |
| Conmed                                         | USA | Linvatec | $554.74 |
| Bionx                                          | Finland | Biofix | $554.74 |
| Gunze                                          | Japan | Grandfix | $416.06 |
| Takiron                                        | Japan | Fixsorb | $408.76 |
| Dikang                                         | China | (PDLLA) | $321.17 |
| ABMT:                                          | China | ABMT | $300.00 |

----

| PHYSICAL COMPARISON     |
|-------------------------|
|                    | Metal | PLLA | ABMT’s PA devices |
| Strength                | Excellent | Weak | Superior to PLLA |
| Unit Cost               | High | Low | Lowest |
| Processability          | Good | Good | Good |
| Modulus of Elasticity   | Low: may cause infection,may cause secondfracture | Moderate to Quite Fragile | Excellent |
| Self-Reinforced         | No | Yes, but degradationstarts too quickly | Yes |
| Self-Resorbable         | No1 | Yes, but initial degradationtoo fast in first fewweeks. Initial strengthdown to 10~20Mpa in 4weeks (close to osteoporosis) | Yes: unchanged duringfirst 12 weeks, hardnessremains 70% minthrough week 20. |
| Stretchability          | Strong | 50~60 Mpa | 170 Mpa (min) |
| Bone Healing            | Bone mineral density decrease averages 18% | Bone mineral density decrease averages 7-10% | Bone mineral density decrease less than 5% |
| Implant Failure Rate    | High to Medium | Medium to Low | Very Low |
| Need for Repeat Surgery | As Required2 | Only if failure  (second fracture) | No |

----

|                             | METAL                                                                                                                                                                                                                                                                                                                                                                                                                              | ABMT’s PA devices                                      |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Cranial Growth                   | • Growth restriction• Intracranial implant migration                                                                                                                                                                                                                                                                                                                                                                   | • Stimulation of growth leading to better bone healing |
| Accumulation of Metal in tissues | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                | No                                                           |
| Adverse Effect                   | • Many necessitate removal operation either for mechanical strength of the overall structure• majority of implant failures occur at the bone-screw interface with screw pullout being the most common mechanistic cause of construct failure• should the bone fail to heal, these micromotions will persist and cause the metallic screw to oscillate within the far softer surrounding bone interface | None                                                         |

| Stiffness for optimal healing | • Too stiff• Stress shielding can result in bone atrophy and degradation                                                                                                                                                                   | • Optimal stiffness/flexibility characteristics to achieve surgical fixation, while conforming to the softer, more pliable bone of the patient                                                              |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other Effects                 | • Implant palpability• Temperature sensitivity• Occasionally visibility• Could cause trauma in the event of mechanical failure• Imaging and radiotherapy interference• Potential for cross contamination | • No long-term palpability• No temperature sensitivity• Predictable degradation• Reduced patient trauma• No imaging and radiotherapy interference• No second surgery required |
| Cost of product               | Cost to hospital: $400-$2200                                                                                                                                                                                                                           | Cost to hospital: $300                                                                                                                                                                                            |

----

| Title: High molecular human body embedding article and its preparing process product and use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  Application Number:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  97119073 |  Application Date: |  1997.10.22 |
|  Publication Number:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |  1214939 |  Publication Date: |  1999.04.28 |
|  Approval Pub. Date:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |   |  Granted Pub. Date: |  2002.08.14 |
|  International Classification:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  A61F2/02,A61L27/00,C08L33/00 |
|  Applicant(s) Name:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |  Liu Jianyu |
|  Address:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |  518111 |
|  Inventor(s) Name:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|  Attorney & Agent:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  Li Zhining |
| Abstract                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| The present invention discloses a macromolecular implant for human body and its preparation process, and relates to the products made up by using said macromolecular implant and their application. Said invented product is made up by using resin fibre through hot-pressing treatment according to the formula provided by said invention, and its strength is high, tenacity is good and its shape can be processed according to the requirement in the period of bone union after implantation, and said implant can be made into the fixation block, eurymeric block, fastening piece and suture for reduction of fracture, and can be started to be degraded from twenty-fourth week after implantation, and can be completely absorbed by human body after 1.5-2 years, and its cost is low. |

----

ITEM 1A. RISK FACTORS

----

ITEM 1B.  UNRESOLVED STAFF COMMENTS

ITEM 2. PROPERTIES

ITEM 3. LEGAL PROCEEDINGS

ITEM 4. REMOVED AND RESERVED

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

| Fiscal Quarter                            |   | High Bid |   |   | Low Bid |   |
|-------------------------------------------|--------|----------|--------|--------|---------|--------|
| 2011                                      |   |     |   |   |    |   |
| Fourth Quarter 08-01-11 to 10-31-11  |   | $        | 2.45   |   |    | $      | 0.20 |   |
| Third Quarter 05-01-11 to 07-31-11   |   | $        | 3.00   |   |    | $      | 0.98 |   |
| Second Quarter 02-01-11 to 04-30-11  |   | $        | 1.04   |   |    | $      | 0.65 |   |
| First Quarter 11-01-10 to 01-31-11   |   | $        | 0.65   |   |    | $      | 0.50 |   |
| Fiscal Quarter                            |   | High Bid |   |   | Low Bid |   |
|-------------------------------------------|--------|----------|--------|--------|---------|--------|
| 2010                                      |   |     |   |   |    |   |   |   |
| Fourth Quarter 08-01-10 to 10-31-10  |   | $        | 1.00   |   |    | $      | 0.06 |   |
| Third Quarter 05-01-10 to 07-31-10   |   | $        | 3.00   |   |    | $      | 3.00 |   |
| Second Quarter 02-01-10 to 04-30-10  |   | $        | 3.00   |   |    | $      | 3.00 |   |
| First Quarter 11-01-09 to 01-31-10   |   | $        | 3.10   |   |    | $      | 3.00 |   |

----

ITEM 6. SELECTED FINANCIAL DATA

----

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

| 1. | The company’s lack of funds in new R&D, especially in clinical testing;                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. | The company’s lack of funds in new equipment and the utilization of the production process after SFDA approval;                                                                                                                                                                                                                                                                                                                                                                                                     |
| 3. | The company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures;                                                                                                                                                                                                                                                                                                                                                                               |
| 4. | The company needs funding for marketing and network build-up;                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 5. | The company plans to seek approval for clinical testing and marketing on a worldwide basis, including US FDA approval for testing and marketing in the United States of America, and there is no guaranty that we will obtain any such approval;                                                                                                                                                                                                                                                                               |
| 6. | While the company currently holds a patent originating in China, the patent does not protect our intellectual property in the United States, and the company is unsure of the validity of the patent in other countries. However, specific trade secrets are involved in the manufacturing of our product to help protect our technologies, and reverse engineering is unlikely for our types of products and technologies. Additionally, all machinery used to manufacture our products is protected by Chinese patents. |

----

| 1. | A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care;                                                                                             |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. | Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit;                                                                                                                                            |
| 3. | Improving the biological activity of materials. Clinical trial results have shown that as PA implants degrade, they promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to ‘stress shielding’; |
| 4. | Reducing the chance of post-operative infection;                                                                                                                                                                                                                       |
| 5. | Effectively controlling the degeneration speed, so that there will be no complications in treating repeat injuries;                                                                                                                                                    |
| 6. | Ease of post-operative care i.e. no distortion during x-ray imaging;                                                                                                                                                                                                   |
| 7. | Simple and cost-effective to manufacture.                                                                                                                                                                                                                              |

----

----

----

| Estimate current production lines in full capacity |                   |
|----------------------------------------------------|------------------------|
|                                             | Output Quantity (Max.) |   | Price atex-factory(US$) |   |   | TotalTurnover(US$) |   |
| PA Screw                                           | 100,000                | (piece) |   |   | 180 |   |   |   | 18,000,000 |   |
| PA Binding Wire                                    | 240,000                | (pack) |   |   | 50 |   |   |   | 12,000,000 |   |
|                                               |                   |   | Total: |   |   |   | 30,000,000 |   |

----

| Statistic and Census report by the Ministry of Health of the People’s Republic of China |
|-----------------------------------------------------------------------------------------------|
| (July 2011)                                                                                   |
|                                                                                          | July 2011 | July 2010 | Increase / (Decrease) |
| Total No. of Hospitals                                                                        | 21,266 | 20,432 | 834 |
| Public Hospital                                                                               | 13,670 | 13,974 | (304) |
| Private Hospital                                                                              | 7,596 | 6,458 | 1,138 |
| Hospital Rating                                                                               |   |   |   |
| AAA                                                                                           | 1,344 | 1,273 | 71 |
| AA                                                                                            | 6,494 | 6,460 | 34 |
| A                                                                                             | 5,321 | 5,147 | 174 |

----

----

----

----

----

----

| 1.     | Property and equipment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Property and equipment are stated at cost, less accumulated depreciation.  Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives.  The estimated useful lives of the assets are 5 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 2.     | Long-lived assets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets”, long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long- lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired.                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 3.     | Fair value of financial instruments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | FASB Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, due from related parties, other payables and accrued liabilities and due to related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 4.     | Government grant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Government grants are recognized when there is reasonable assurance that the Company complies with any conditions attached to them and the grants will be received.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 5.     | Income taxes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date. |

----

| 6.                               | Research and Development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | Research and development costs related to both present and future products are expensed as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 7.                               | Foreign currency translation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | The financial statements of the Company’s subsidiary denominated in currencies other than US $are translated into US $using the closing rate method.  The balance sheet items are translated into US $using the exchange rates at the respective balance sheet dates.  The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year.  All exchange differences are recorded within equity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| RECENT ACCOUNTING PRONOUNCEMENTS |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | On September 15, 2011 the FASB issued Accounting Standards Update (“ASU”) 2011-08, Testing Goodwill for Impairment (the revised standard). The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing both public and nonpublic entities with the option of performing a “qualitative” assessment to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. The revised standard is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted for certain companies. The Company has assessed the potential impact the adoption of ASU 2011-08 on its consolidated results of operations and consolidated financial position and concluded that there is no impact.                                                                                                                                       |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | In July 2011, the FASB issued ASU 2011-07, Health Care Entities (Topic 954), which requires healthcare organizations that perform services for patients for which the ultimate collection of all or a portion of the amounts billed or billable cannot be determined at the time services are rendered to present all bad debt expense associated with patient service revenue as an offset to the patient service revenue line item in the statement of operations. The ASU also requires qualitative disclosures about the Company’s policy for recognizing revenue and bad debt expense for patient service transactions and quantitative information about the effects of changes in the assessment of collectability of patient service revenue. This ASU is effective for fiscal years beginning after December 15, 2011, and will be adopted by the Company in the first quarter of 2012. Since the Company is not a health care entity, the standard does not have any impact on the Company’s consolidated financial position or results of operations.                                                          |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | In June 2011 the FASB issued ASU No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income, which amends current comprehensive income guidance”. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of stockholders’ equity. Instead, companies must report comprehensive income in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 will be effective during the interim and annual periods beginning after December 15, 2011 with early adoption permitted. The Company will adopt ASU 2011-05 in the first quarter of fiscal year 2012. The Company does not expect that the adoption of ASU 2011-05 will have a material impact on the Company’s Consolidated Financial Statements.                                                                                                                                                              |
|                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                             | In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.” The amendments in this ASU generally represent clarification of Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This update results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with GAAP and International Financial Reporting Standards (“IFRS”). The amendments are effective for interim and annual periods beginning after December 15, 2011 and are to be applied prospectively. Early application is not permitted. The Company does not expect the adoption of ASU 2011-04 will have a material impact on the Company’s Consolidated Financial Statements. |

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

----

----

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

----

----

| Pages                                                        |
|--------------------------------------------------------------|
| Reports of Independent Registered Public Accounting Firm     |   | F-1 |
| Consolidated Balance Sheets                                  |   | F-2 |
| Consolidated Statements of Operations and Comprehensive Loss |   | F-3 |
| Consolidated Statements of Stockholders’ Deficiency    |   | F-4 |
| Consolidated Statements of Cash Flows                        |   | F-5 |
| Notes to Consolidated Financial Statements                   |   | F-6 – F-12 |

----

----

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

----

----

CONSOLIDATED BALANCE SHEETS

| ASSETS                                                                                                                                                                         |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                                                           |   | October 31, |   |   | October 31, |   |
|                                                                                                                                                                           |   | 2011 |   |   | 2010 |   |
|                                                                                                                                                                           |   |   |   |   |   |   |
| CURRENT ASSETS                                                                                                                                                                 |   |   |   |   |   |   |
| Cash and cash equivalents                                                                                                                                                      |   | $ | 78,781 |   |   | $ | 38,614 |   |
| Other receivables and prepaid expenses                                                                                                                                         |   |   | 21,933 |   |   |   | 12,623 |   |
| Total Current Assets                                                                                                                                                           |   |   | 100,714 |   |   |   | 51,237 |   |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| PROPERTY AND EQUIPMENT, NET                                                                                                                                                    |   |   | 103,170 |   |   |   | 49,461 |   |
| DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT                                                                                                                                 |   |   | 9,628 |   |   |   | — |   |
| TOTAL ASSETS                                                                                                                                                                   |   | $ | 213,512 |   |   | $ | 100,698 |   |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                                    |   |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                                                                                                            |   |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                                                                                                                            |   | $ | 44,536 |   |   | $ | 25,711 |   |
| Due to a stockholder                                                                                                                                                           |   |   | 147,137 |   |   |   | 217,951 |   |
| Due to directors                                                                                                                                                               |   |   | 558,467 |   |   |   | 158,941 |   |
| Due to a related company                                                                                                                                                       |   |   | — |   |   |   | 400,192 |   |
| Due to related parties                                                                                                                                                         |   |   | 1,026,142 |   |   |   | 788,400 |   |
| Total Current Liabilities                                                                                                                                                      |   |   | 1,776,282 |   |   |   | 1,591,195 |   |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                                                                                                                  |   |   | — |   |   |   | — |   |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| DEFICIT                                                                                                                                                                        |   |   |   |   |   |   |   |   |
| ABMT Stockholders’ Deficit                                                                                                                                               |   |   |   |   |   |   |   |   |
| Common stock, $0.00001 par value, 100,000,000 shares authorized,  56,474,850 and 56,144,850 shares issued and outstanding as of October 31, 2011 and  2010 |   |   | 565 |   |   |   | 562 |   |
| Common stock, 230,000 shares to be issued                                                                                                                                      |   |   | — |   |   |   | 2 |   |
| Stock subscription receivable                                                                                                                                                  |   |   | — |   |   |   | (230,000 | ) |
| Additional paid-in capital                                                                                                                                                     |   |   | 1,626,610 |   |   |   | 1,494,551 |   |
| Deferred stock compensation                                                                                                                                                    |   |   | (87,501 | ) |   |   | (206,459 | ) |
| Accumulated deficit during development stage                                                                                                                                   |   |   | (2,923,483 | ) |   |   | (2,436,044 | ) |
| Accumulated other comprehensive loss                                                                                                                                           |   |   | (178,961 | ) |   |   | (113,109 | ) |
| Total ABMT Stockholders’ Deficit                                                                                                                                         |   |   | (1,562,770 | ) |   |   | (1,490,497 | ) |
|                                                                                                                                                                           |   |   |   |   |   |   |   |   |
| Noncontrolling interests                                                                                                                                                       |   |   | — |   |   |   | — |   |
| Total Deficit                                                                                                                                                                  |   |   | (1,562,770 | ) |   |   | (1,490,497 | ) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                              |   | $ | 213,512 |   |   | $ | 100,698 |   |

----

----

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

|                                                                           |   | Year ended  |       |   | September 25, 2002  |   |
|--------------------------------------------------------------------------------|--------|-------------|------------|--------|---------------------|--------|
|                                                                           |   | October 31, |       |   | (Inception) through |   |
|                                                                           |   | 2011        |       |   | 2010                |   |   | October 31, 2011 |   |
|                                                                           |   |        |       |   |                |   |   |   |   |
| OPERATING EXPENSES                                                             |   |        |       |   |                |   |   |   |   |
| General and administrative expenses                                            |   | $           | 608,806    |   |                | $      | 687,210 |   |   | $ | 2,591,175 |   |
| Depreciation                                                                   |   |        | 5,940      |   |                |   | 22,096 |   |   |   | 267,310 |   |
| Research and development (Net of government grant)                        |   |        | 19,734     |   |                |   | 11,686 |   |   |   | 138,767 |   |
| Total Operating Expenses                                                       |   |        | 634,480    |   |                |   | 720,992 |   |   |   | 2,997,252 |   |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS                                                           |   |        | (634,480   | )      |                |   | (720,992 | ) |   |   | (2,997,252 | ) |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSES)                                                        |   |        |       |   |                |   |   |   |   |   |   |   |
| Government grants                                                              |   |        | 244,479    |   |                |   | — |   |   |   | 244,479 |   |
| Interest income                                                                |   |        | 94         |   |                |   | 103 |   |   |   | 1,695 |   |
| Interest paid to a stockholder and related parties                        |   |        | (61,053    | )      |                |   | (59,272 | ) |   |   | (161,448 | ) |
| Imputed interest                                                               |   |        | (27,060    | )      |                |   | (28,356 | ) |   |   | (204,144 | ) |
| Other, net                                                                     |   |        | (9,419     | )      |                |   | (8,282 | ) |   |   | (24,018 | ) |
| Total Other Income (Expenses), net                                             |   |        | 147,041    |   |                |   | (95,807 | ) |   |   | (143,436 | ) |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| LOSS FROM OPERATIONS BEFORE TAXES                                              |   |        | (487,439   | )      |                |   | (816,799 | ) |   |   | (3,140,688 | ) |
| Income tax expense                                                             |   |        | —    |   |                |   | — |   |   |   | — |   |
| NET LOSS                                                                       |   |        | (487,439   | )      |                |   | (816,799 | ) |   |   | (3,140,688 | ) |
| Net loss attributable to noncontrolling interests                              |   |        | —    |   |                |   | — |   |   |   | 217,205 |   |
| NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS                              |   |        | (487,439   | )      |                |   | (816,799 | ) |   |   | (2,923,483 | ) |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| OTHER COMPREHENSIVE LOSS                                                       |   |        |       |   |                |   |   |   |   |   |   |   |
| Total other comprehensive loss                                                 |   |        | (65,852    | )      |                |   | (29,063 | ) |   |   | (178,961 | ) |
| Add: foreign currency translation loss attributable to noncontrolling interest |   |        | —    |   |                |   | — |   |   |   | — |   |
| Foreign currency translation loss attributable to ABMT common stockholders     |   |        | (65,852    | )      |                |   | (29,063 | ) |   |   | (178,961 | ) |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS                    |   | $           | (553,291   | )      |                | $      | (845,862 | ) |   | $ | (3,102,444 | ) |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| Net loss per share-basic and diluted                                           |   | $           | (0.01      | )      |                | $      | (0.02 | ) |   |   |   |   |
|                                                                           |   |        |       |   |                |   |   |   |   |   |   |   |
| Weighted average number of shares outstanding during the year                  |   |        |       |   |                |   |   |   |   |   |   |   |
| - basic and diluted                                                            |   |        | 56,417,042 |   |                |   | 55,864,524 |   |   |   |   |   |

----

----

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

|                                                                               |   |            |       |                |   |            |   |       |     |                    |   | Accumulated    |   |  Accumulated |     |             |   |              |   |
|------------------------------------------------------------------------------------|--------|-----------------|------------|---------------------|--------|-----------------|--------|------------|----------|-------------------------|--------|----------------|--------|-------------------|----------|------------------|--------|-------------------|--------|
|                                                                               |   | Common Stock    |       | Shares to be issued |   | Stock           |   | Additional |     | Deferred                |   | deficit during |   | other             |     |             |   |              |   |
|                                                                               |   | Numberof Shares |       | Amount              |   | Number ofShares |   | Amount     |     | subscriptionsreceivable |   | Paid-incapital |   | StockCompensation |     | developmentstage |   | comprehensiveloss |   | Noncontrollinginterests |   | Total |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |
| Stock issued to founders for cash                                                  |   |            | 50,510,000 |                | $      | 505             |   |       | —  |                    | $      | —        |   | $                 | —  |             | $      | 275,002           |   | $ | — |   | $ | — |   | $ | — |   | $ | 217,205 |   | $ | 492,712 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                            |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (40,343 | ) |   | — |   |   | (17,290 | ) |   | (57,633 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (225 | ) |   | 10 |   |   | (215 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (57,848 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2003                                                       |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 275,002           |   |   | — |   |   | (40,343 | ) |   | (225 | ) |   | 199,925 |   |   | 434,864 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (65,960 | ) |   | — |   |   | (28,269 | ) |   | (94,229 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (357 | ) |   | 2 |   |   | (355 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (94,584 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2004                                                       |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 275,002           |   |   | — |   |   | (106,303 | ) |   | (582 | ) |   | 171,658 |   |   | 340,280 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 23,103            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 23,103 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (357,863 | ) |   | — |   |   | (153,370 | ) |   | (511,233 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (12,290 | ) |   | 2,064 |   |   | (10,226 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (521,459 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2005                                                       |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 298,105           |   |   | — |   |   | (464,166 | ) |   | (12,872 | ) |   | 20,352 |   |   | (158,076 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 27,184            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 27,184 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (172,738 | ) |   | — |   |   | (18,276 | ) |   | (191,014 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (6,084 | ) |   | (2,076 | ) |   | (8,160 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (199,174 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2006                                                       |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 325,289           |   |   | — |   |   | (636,904 | ) |   | (18,956 | ) |   | — |   |   | (330,066 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder, related company and related party |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 39,021            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 39,021 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (196,871 | ) |   | — |   |   | — |   |   | (196,871 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (27,401 | ) |   | — |   |   | (27,401 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (224,272 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at December 31, 2007                                                       |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 364,310           |   |   | — |   |   | (833,775 | ) |   | (46,357 | ) |   | — |   |   | (515,317 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 27,764            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 27,764 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period                                                            |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (227,038 | ) |   | — |   |   | — |   |   | (227,038 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (35,833 | ) |   | — |   |   | (35,833 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (262,871 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31,2008                                                         |   |            | 50,510,000 |                |   | 505             |   |       | —  |                    |   | —        |   |              | —  |             |   | 392,074           |   |   | — |   |   | (1,060,813 | ) |   | (82,190 | ) |   | — |   |   | (750,424 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Recapitalization                                                                   |   |            | 5,104,000  |                |   | 51              |   |       | —  |                    |   | —        |   |              | —  |             |   | (51               | )      |   | — |   |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($3.05 per share)                                        |   |            | 100,000    |                |   | 1               |   |       | —  |                    |   | —        |   |              | —  |             |   | 304,999           |   |   | (292,292 | ) |   | — |   |   | — |   |   | — |   |   | 12,708 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)                       |   |            | 5,000      |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 5,750             |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 5,750 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.15 per share)                       |   |            | 2,000      |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 2,300             |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 2,300 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Contributed capital                                                                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 26,950            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 26,950 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Distributed to the stockholders                                                    |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | (31,409           | )      |   | — |   |   | — |   |   | — |   |   | — |   |   | (31,409 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed Interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 31,656            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 31,656 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (558,432 | ) |   | — |   |   | — |   |   | (558,432 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (1,856 | ) |   | — |   |   | (1,856 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (560,288 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at October 31, 2009                                                        |   |            | 55,721,000 |                |   | 557             |   |       | —  |                    |   | —        |   |              | —  |             |   | 732,269           |   |   | (292,292 | ) |   | (1,619,245 | ) |   | (84,046 | ) |   | — |   |   | (1,262,757 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                        |   |            | 6,667      |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 10,000            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 10,000 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                        |   |            | 16,667     |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 25,000            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 25,000 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.5 per share)                        |   |            | 136,833    |                |   | 2               |   |       | —  |                    |   | —        |   |              | —  |             |   | 205,248           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 205,250 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock to be issued for cash in private placement ($1.0 per share)                  |   |            | —    |                |   | —         |   |       | 230,000  |                    |   | 2              |   |              | (230,000 | )                |   | 229,998           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                           |   |            | 100,000    |                |   | 1               |   |       | —  |                    |   | —        |   |              | —  |             |   | 99,999            |   |   | (100,000 | ) |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                           |   |            | 13,683     |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 13,683            |   |   | (13,683 | ) |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for services ($1 per share)                                           |   |            | 150,000    |                |   | 2               |   |       | —  |                    |   | —        |   |              | —  |             |   | 149,998           |   |   | (150,000 | ) |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                                         |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | 349,516 |   |   | — |   |   | — |   |   | — |   |   | 349,516 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 28,356            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 28,356 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (816,799 | ) |   | — |   |   | — |   |   | (816,799 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (29,063 | ) |   | — |   |   | (29,063 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (845,862 | ) |
| Balance at October 31, 2010                                                        |   |            | 56,144,850 |                |   | 562             |   |       | 230,000  |                    |   | 2              |   |              | (230,000 | )                |   | 1,494,551         |   |   | (206,459 | ) |   | (2,436,044 | ) |   | (113,109 | ) |   | — |   |   | (1,490,497 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1 per share)                          |   |            | 230,000    |                |   | 2               |   |       | (230,000 | )                       |   | (2             | )      |              | 230,000  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 230,000 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock issued for cash in private placement ($1.05 per share)                       |   |            | 100,000    |                |   | 1               |   |       | —  |                    |   | —        |   |              | —  |             |   | 104,999           |   |   | (105,000 | ) |   | — |   |   | — |   |   | — |   |   | — |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Imputed interest on advances from a stockholder and related company                |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | 27,060            |   |   | — |   |   | — |   |   | — |   |   | — |   |   | 27,060 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Amortisation for stock issued for services                                         |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | 223,958 |   |   | — |   |   | — |   |   | — |   |   | 223,958 |   |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the year                                                              |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | (487,439 | ) |   | — |   |   | — |   |   | (487,439 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation loss                                                  |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | (65,852 | ) |   | — |   |   | (65,852 | ) |
|                                                                               |   |            |       |                |   |            |   |       |     |                    |   |           |   |              |     |             |   |              |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                                 |   |            | —    |                |   | —         |   |       | —  |                    |   | —        |   |              | —  |             |   | —           |   |   | — |   |   | — |   |   | — |   |   | — |   |   | (553,291 | ) |
| Balance at October 31, 2011                                                        |   |            | 56,474,850 |                | $      | 565             |   |       | —  |                    | $      | —        |   | $                 | —  |             | $      | 1,626,610         |   | $ | (87,501 | ) | $ | (2,923,483 | ) | $ | (178,961 | ) | $ | — |   | $ | (1,562,770 | ) |

----

----

CONSOLIDATED STATEMENTS OF CASH FLOWS

|                                                                    |   |                  |     |   | September 25, 2002 |   |
|-------------------------------------------------------------------------|--------|-----------------------|----------|--------|--------------------|--------|
|                                                                    |   | Year endedOctober 31, |     |   | (inception)through |   |
|                                                                    |   | 2011                  |     |   | 2010               |   |   | October 31, 2011 |   |
|                                                                    |   |                  |     |   |               |   |   |   |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                    |   |                  |     |   |               |   |   |   |   |
| Net loss attributable to ABMT common stockholders                       |   | $                     | (487,439 | )      |               | $      | (816,799 | ) |   | $ | (2,923,483 | ) |
| Adjustments to reconcile net loss to cash used in operating activities: |   |                  |     |   |               |   |   |   |   |   |   |   |
| Depreciation                                                            |   |                  | 5,940    |   |               |   | 22,096 |   |   |   | 267,310 |   |
| Loss on disposal of fixed assets                                        |   |                  | 8,308    |   |               |   | 5,328 |   |   |   | 11,704 |   |
| Stock issued for services                                               |   |                  | 223,958  |   |               |   | 349,516 |   |   |   | 586,183 |   |
| Noncontrolling interests                                                |   |                  | —  |   |               |   | — |   |   |   | (217,205 | ) |
| Imputed interest                                                        |   |                  | 27,060   |   |               |   | 28,356 |   |   |   | 204,144 |   |
| Changes in operating assets and liabilities                             |   |                  |     |   |               |   |   |   |   |   |   |   |
| (Increase) decrease in:                                                 |   |                  |     |   |               |   |   |   |   |   |   |   |
| Other receivables and prepaid expenses                                  |   |                  | (8,469   | )      |               |   | 8,145 |   |   |   | (21,933 | ) |
| Increase (decrease) in:                                                 |   |                  |     |   |               |   |   |   |   |   |   |   |
| Other payables and accrued expenses                                     |   |                  | 18,615   |   |               |   | (5,052 | ) |   |   | 44,536 |   |
| Net cash used in operating activities                                   |   |                  | (212,027 | )      |               |   | (408,410 | ) |   |   | (2,048,744 | ) |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| Purchase of property and equipment                                      |   |                  | (47,843  | )      |               |   | (5,638 | ) |   |   | (365,063 | ) |
| Construction in progress                                                |   |                  | (16,708  | )      |               |   | — |   |   |   | (17,121 | ) |
| Deposit for purchase of property and equipment                          |   |                  | (9,396   | )      |               |   | — |   |   |   | (9,628 | ) |
| Net cash used in investing activities                                   |   |                  | (73,947  | )      |               |   | (5,638 | ) |   |   | (391,812 | ) |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| Stock issued to founders                                                |   |                  | —  |   |               |   | — |   |   |   | 505 |   |
| Proceeds from issuance of shares                                        |   |                  | 230,000  |   |               |   | 240,250 |   |   |   | 478,300 |   |
| Contribution by stockholders                                            |   |                  | —  |   |               |   | — |   |   |   | 519,157 |   |
| Distributed to stockholders                                             |   |                  | —  |   |               |   | — |   |   |   | (31,409 | ) |
| Due to a stockholder                                                    |   |                  | (71,204  | )      |               |   | (117,793 | ) |   |   | 147,137 |   |
| Due to directors                                                        |   |                  | 382,798  |   |               |   | (66,051 | ) |   |   | 558,467 |   |
| Due to a related company                                                |   |                  | (410,019 | )      |               |   | — |   |   |   | — |   |
| Due to related parties                                                  |   |                  | 190,768  |   |               |   | 384,919 |   |   |   | 1,026,142 |   |
| Net cash provided by financing activities                               |   |                  | 322,343  |   |               |   | 441,325 |   |   |   | 2,698,299 |   |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS            |   |                  | 3,798    |   |               |   | 731 |   |   |   | (178,962 | ) |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| NET INCREASE IN CASH AND CASH EQUIVALENTS                               |   |                  | 40,167   |   |               |   | 28,008 |   |   |   | 78,781 |   |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR                          |   |                  | 38,614   |   |               |   | 10,606 |   |   |   | — |   |
|                                                                    |   |                  |     |   |               |   |   |   |   |   |   |   |
| CASH AND CASH EQUIVALENTS AT END OF YEAR                                |   | $                     | 78,781   |   |               | $      | 38,614 |   |   | $ | 78,781 |   |

----

----

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

----

| 1.     | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION |
|--------|-------------------------------------------------------------|
|   |                                                        |   |
|   | (A)                                                         | Organization |
|   |                                                        |   |
|   |                                                        | Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006 . |
|   |                                                        |   |
|   |                                                        | Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua plans to develop, manufacture and market self-reinforced, re-absorbable degradable PA screws, robs and binding ties for fixation on human fractured bones. The Company is currently conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially pending the approval from the State Food and Drug Administration (“SFDA”) of the PRC on its products. The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company. |
|   |                                                        |   |
|   |                                                        | Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation. |
|   |                                                        |   |
|   |                                                        | On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively. |
|   |                                                        |   |
|   |                                                        | On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise. |
|   |                                                        |   |
|   |                                                        | Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise. |
|   |                                                        |   |
|   |                                                        | On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT. |
|   |                                                        |   |
|   |                                                        | On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc. |
|   |                                                        |   |
|   |                                                        | The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively. |
|   |                                                        |   |
|   |                                                        | Accordingly, these financial statements include the following: |

|   | (1)    | The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.                            |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                |
|   | (2)    | The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction. |

|   |   | ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”) |
|--------|--------|--------------------------------------------------------------------------------------------------|
|   |   |                                                                                             |
|   | (B)    | Principles of consolidation                                                                      |

----

|   |   | The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | All significant inter-company balances and transactions have been eliminated in consolidation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (C)    | Use of estimates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (D)    | Cash and cash equivalents                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2011 and 2010, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (E)    | Property and equipment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (F)    | Long-lived assets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Goodwill and Other Intangible Assets” and “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment annually during the fourth quarter or more frequently if events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2011 and 2010, the Company has not recognized any allowances for impairment. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (G)    | Fair value of financial instruments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | FASB Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, due from related parties, other payables and accrued liabilities and due to related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.                                                                                                                                                                                                                                                                                                                                                                           |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (H)    | Government grant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | Government grants are recognized when there is reasonable assurance that the Company complies with any conditions attached to them and the grants will be received.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | In April 2011, the Company was informed of approval of one grant totaling $244,479 under the Qualified Therapeutic Discovery Project Grants Program. The Qualified Therapeutic Discovery Project Grants Program was included in the healthcare reform legislation, and established a one-time pool of $1 billion for grants to small biotechnology companies developing novel therapeutics which show potential to: (a) result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions; (b) reduce long-term health care costs in the United States; or (c) significantly advance the goal of curing cancer within a 30-year period. The grant was received on May 6, 2011. There are no matching funding requirements or other requirements necessary to receive the funding and, therefore, the grant is classified as other income.                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | (I)    | Income taxes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   | The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

----

|   |   | in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.                                                                                                                                                                                                                                                                                                               |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | (J)    | Research and Development                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |   | Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2011 and 2010, and for the period from September 25, 2002 (inception) through October 31, 2011 was $19,734, $11,686 and $138,767 respectively.                                                                                                                                                                               |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | (K)    | Foreign currency translation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |   | ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$and RMB respectively.                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |   | Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.                         |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |   | The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$and RMB respectively) are translated into US$using the closing rate method. The balance sheet items are translated into US$using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |   | The exchange rates used to translate amounts in HK$and RMB into US$for the purposes of preparing the financial statements were as follows:                                                                                                                                                                                                                                                                                                                                                                                                                     |

|                                                                                                               |   | October 31,2011          |   | October 31, 2010           |
|--------------------------------------------------------------------------------------------------------------------|--------|--------------------------|--------|----------------------------|
| Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end |   | US$1=HK$7.7641=RMB6.3547 |   | US$1=HK$7.7524=RMB6.67180  |
|                                                                                                               |   |                     |   |                       |
| Amounts included in the statements of operations and cash flows for the year                                       |   | US$1=HK$7.7817=RMB6.5119 |   | US$1=HK$7.76739=RMB6.80784 |

|   |   | The translation loss recorded for the years ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) through October 31, 2011 was $65,852, $29,063 and $178,961 respectively.                                                                                                                                                                                                                                                                                              |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |   | No presentation is made that RMB amounts have been, or would be, converted into US$at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$at that rate or any other rate.                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |   | The value of RMB against US$and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions, Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$reporting.                                                                                                                                                                                                            |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | (L)    | Other comprehensive loss                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |   | The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$to US$is reported as other comprehensive gain (loss) in the statements of operations and stockholders’ equity. Other comprehensive loss for the years ended October 31, 2011 and 2010, and for the period from September 25, 2002 (inception) through October 31, 2011, was $65,852, $29,063 and $178,961 respectively                                                |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | (M)    | Earnings per share                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |   | Basic earnings per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted income per share is computed similar to basic income per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There were no potentially dilutive securities for 2011 and 2010. |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | (N)    | Segments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

----

|   |                                                                               | The Company operates in only one segment, thereafter segment disclosure is not presented.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   | (O)                                                                                | Recent Accounting Pronouncements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                               | On September 15, 2011 the FASB issued Accounting Standards Update (“ASU”) 2011-08, Testing Goodwill for Impairment (the revised standard). The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing both public and nonpublic entities with the option of performing a “qualitative” assessment to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. The revised standard is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted for certain companies. The Company has assessed the potential impact the adoption of ASU 2011-08 on its consolidated results of operations and consolidated financial position and concluded that there is no impact.                                                                                                                             |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                               | In July 2011, the FASB issued ASU 2011-07, Health Care Entities (Topic 954), which requires healthcare organizations that perform services for patients for which the ultimate collection of all or a portion of the amounts billed or billable cannot be determined at the time services are rendered to present all bad debt expense associated with patient service revenue as an offset to the patient service revenue line item in the statement of operations. The ASU also requires qualitative disclosures about the Company’s policy for recognizing revenue and bad debt expense for patient service transactions and quantitative information about the effects of changes in the assessment of collectability of patient service revenue. This ASU is effective for fiscal years beginning after December 15, 2011, and will be adopted by the Company in the first quarter of 2012. Since the Company is not a health care entity, the standard does not have any impact on the Company’s consolidated financial position or results of operations.                                                |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                               | In June 2011 the FASB issued ASU No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income, which amends current comprehensive income guidance”. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of stockholders’ equity. Instead, companies must report comprehensive income in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 will be effective during the interim and annual periods beginning after December 15, 2011 with early adoption permitted. The Company will adopt ASU 2011-05 in the first quarter of fiscal year 2012. The Company does not expect that the adoption of ASU 2011-05 will have a material impact on the Company’s Consolidated Financial Statements.                                                                                                                                                    |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                               | In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs.” The amendments in this ASU generally represent clarification of Topic 820, but also include instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements has changed. This update results in common principles and requirements for measuring fair value and for disclosing information about fair value measurements in accordance with GAAP and International Financial Reporting Standards (“IFRS”). The amendments are effective for interim and annual periods beginning after December 15, 2011 and are to be applied prospectively. Early application is not permitted. The Company does not expect the adoption of ASU 2011-04 will have a material impact on the Company’s Consolidated Financial Statements. |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 2.     | PROPERTY AND EQUIPMENT                                                             |
|   |                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   | The following is a summary of property and equipment at October 31, 2011 and 2010: |

|                           |   | October 31, |    |
|--------------------------------|--------|-------------|---------|
|                           |   | 2011        |    |   | 2010 |   |
|                           |   |        |    |   |   |   |
| Plant and machinery            |   | $           | 176,803 |   |   | $ | 155,201 |   |
| Motor vehicles                 |   |        | 43,385  |   |   |   | 41,323 |   |
| Office equipment               |   |        | 25,777  |   |   |   | 25,029 |   |
| Computer software              |   |        | 5,017   |   |   |   | — |   |
| Office improvements            |   |        | 126,427 |   |   |   | 120,418 |   |
| Construction in progress       |   |        | 17,121  |   |   |   | — |   |
|                           |   |        | 394,530 |   |   |   | 341,971 |   |
| Less: accumulated depreciation |   |        | 291,360 |   |   |   | 292,510 |   |
|                           |   |        |    |   |   |   |   |   |
| Property and equipment, net    |   | $           | 103,170 |   |   | $ | 49,461 |   |

|   | Depreciation expense for the year ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) |
|--------|--------------------------------------------------------------------------------------------------------------------------|

----

|   | through October 31, 2011 was $5,940, $22,096 and $267,310 respectively. |
|--------|-------------------------------------------------------------------------|

| 3.     | OTHER PAYABLES AND ACCRUED EXPENSES                                                          |
|--------|----------------------------------------------------------------------------------------------|
|   |                                                                                         |
|   | Other payables and accrued expenses at October 31, 2011 and 2010 consisted of the following: |

|             |   | October 31, |   |
|------------------|--------|-------------|--------|
|             |   | 2011        |   |   | 2010 |   |
|             |   |        |   |   |   |   |
| Other payables   |   | $           | 253    |   |   | $ | 427 |   |
| Accrued expenses |   |        | 44,283 |   |   |   | 25,344 |   |
|             |   | $           | 44,536 |   |   | $ | 25,771 |   |

| 4.     | RELATED PARTY TRANSACTIONS                                                                                                                                                                                                                                                                                     |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                           |
|   | As of October 31, 2011 and 2010, the Company owed $147,137 and $217,951 respectively to a stockholder which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                           |
|   | As of October 31, 2011 and 2010, the Company owed $1,026,142 and $788,400 to two related parties which are unsecured and repayable on demand. Interests are charged at 7% per annum on the amount owed.                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                           |
|   | Total interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) through October 31, 2011 were $61,053, $59,272 and $161,448 respectively.                                          |
|   |                                                                                                                                                                                                                                                                                                           |
|   | As of October 31, 2011 and 2010, the Company owed $558,467 and $158,941 respectively to three directors for advances made. These advances were made on an unsecured basis, repayable on demand and interest free.                                                                                              |
|   |                                                                                                                                                                                                                                                                                                           |
|   | As of October 31, 2011 and 2010, the Company owed $0 and $400,192 respectively to a related company on an unsecured basis, repayable on demand and interest free.                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                           |
|   | Imputed interest on the amounts owed to three directors and a related company are $27,060, $28,356 and $204,144 for the years ended October 31, 2011, and 2010 and for the period from September 25, 2002 (inception) through October 31, 2011 respectively.                                                   |
|   |                                                                                                                                                                                                                                                                                                           |
|   | For the years ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) through October 31, 2011, the Company paid two directors $10,000, $0 and $10,000 respectively for consultancy services.                                                                                   |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On October 26, 2010, the Company issued 150,000 shares of restricted common stock at $1 to a director for advisory services. The shares were valued at the recent cash offering price, yielding an aggregate fair value of $150,000.                                                                           |
|   |                                                                                                                                                                                                                                                                                                           |
| 5.     | STOCKHOLDERS’ DEFICIENCY                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                           |
|   | Common stock                                                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On March 16, 2010, the Company entered into a subscription agreement with an investor for the issue of 136,833 shares of common stock at $1.5 per share for cash. The total subscription amount of $205,250 was received on March 16, 2010 and the 136,833 shares were issued to the investor on May 13, 2010. |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On July 17, 2010, the Company issued 100,000 shares of restricted common stock at $1 to the Chief Medical Advisor for his advisory services. The shares were valued at the closing price on the date of grant, yielding an aggregate fair value of $100,000.                                                   |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On September 30, 2010, the Company issued 13,683 shares of restricted common stock at $1 for advisory services. The shares were valued at the recent cash offering price, yielding an aggregate fair value of $13,683.                                                                                         |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On October 26, 2010, the Company issued 150,000 shares of restricted common stock at $1 to a director for advisory services. The shares were valued at the recent cash offering price, yielding an aggregate fair value of $150,000.                                                                           |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On October 28, 2010, the Company issued 230,000 shares of common stock at $1 for cash in a private placement.                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                           |
|   | On May 31, 2011, the Company issued 100,000 shares of restricted common stock at $1.05 for advisory services. The shares were valued at the closing price on the date of grant, yielding an aggregate fair value of $105,000.                                                                                  |
|   |                                                                                                                                                                                                                                                                                                           |
|   | For the years ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) through October 31,                                                                                                                                                                                       |

----

|   | 2011, the Company recognized $223,958, $349,516 and $586,182 respectively as consultancy fees included in general and administrative expenses and recorded deferred stock compensation of $87,501 and $206,459 as of October 31, 2011 and 2010 for these services. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                               |   |
| 6.     | COMMITMENTS AND CONTINGENCIES                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                               |   |
|   | (A)                                                                                                                                                                                                                                                                | Employee benefits |
|   |                                                                                                                                                                                                                                                               |   |
|   |                                                                                                                                                                                                                                                               | The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $15,988, $7,304 and $38,854 for the years ended October 31, 2011 and 2010 and for the period from September 25, 2002 (inception) through October 31, 2011 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees. |
|   |                                                                                                                                                                                                                                                               |   |
|   | (B)                                                                                                                                                                                                                                                                | Lease commitments |
|   |                                                                                                                                                                                                                                                               |   |
|   |                                                                                                                                                                                                                                                               | The Company leased office space from a third party under an operating lease at monthly rental of $1,951 subject to an annual increase of 5% in each year. The lease expires on July 20, 2014. The Company also leases six apartments for staff under three operating leases with a third party at monthly rental totaling $546, all of which expire in July 2012. |
|   |                                                                                                                                                                                                                                                               |   |
|   |                                                                                                                                                                                                                                                               | As of October 31, 2011, the Company had outstanding commitments with respect to the above operating lease, which are due as follows: |

| 2012  |   | $      | 28,994  |   |
|-------|--------|--------|---------|--------|
| 2013  |   |   | 25,604  |   |
| 2014  |   |   | 19,309  |   |
| 2015  |   |   | — |   |
| Total |   | $      | 73,907  |   |

| 7.     | INCOME TAX                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2011 and 2010. ABMT has net operating loss carry forwards for income taxes amounting to approximately $313,376 and 261,232 as of October 31, 2011 and 2010 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2011 and 2010 was $313,376 and $261,232 respectively. The net change in the valuation allowance for 2011 was an increase of $52,144. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 8.     | CONCENTRATIONS AND RISKS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | During 2011 and 2010, 81%, 19%, 96% and 4% of the Company’s assets were located in the PRC and the United States respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 9.     | GOING CONCERN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   | As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $2,923,483 as of October 31, 2011 that includes a net loss of $487,439 for the year ended October 31, 2011. The Company’s total current liabilities exceed its total current assets by $1,675,568 and the Company used cash in operations of $212,027. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing                                                                                                                                                                                                     |

----

|   | and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                        |
|   | To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.              |

----

----

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

ITEM 9A. CONTROLS AND PROCEDURES.

----

ITEM 9B. OTHER INFORMATION

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

| Name and Address |   | Age |   | Position(s)                                  |
|------------------|--------|-----|--------|----------------------------------------------|
| Chi Ming YU      |   | 38  |   | President, Director                          |
| WANG Hui         |   | 42  |   | Chief Executive Officer, Director            |
| Kai GUI          |   | 42  |   | Director, Secretary, Chief Financial Officer |

----

|   | 1. | Any petition under the Federal bankruptcy laws or any state insolvency law being filed by or against, or a receiver, fiscal agent or similar officer being appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 2.     | Conviction in a criminal proceeding, or being a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | 3.     | Being the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:                                                                                                                                                                                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | i.     | Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | ii.    | Engaging in any type of business practice; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | iii.   | Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;                                                                                                                                                                                                                                                                                                                                                                                      |
|   |   |
|   | 4.     | Being the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity;                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | 5.     | Being found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;                                                                                                                                                                                                                                                                                          |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | 6.     | Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;                                                                                                                                                                                                                                                                       |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | 7.     | Being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:                                                                                                                                                                                                                                                                                                                                                                              |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | i.     | Any Federal or State securities or commodities law or regulation; or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   | ii.    | Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or                                                                                                                                                                                                                                                                                      |

----

|   | iii.   | Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or                                                                                                                                                                                                                                                                                                                                                                                 |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|   | 8.     | Being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. |

----

ITEM 11. EXECUTIVE COMPENSATION

| Executive Officer Compensation Table |    |
|--------------------------------------|---------|
|                                 |    | Fees |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                 |    | Earned |   |   |   |   |   |   |   |   |   |   |   | Nonqualified |   |   |   |   |   |   |   |
|                                 |    | or |   |   |   |   |   |   |   |   | Non-Equity |   |   | Deferred |   |   |   |   |   |   |   |
|                                 |    | Paid in |   |   | Stock |   |   | Option |   |   | Incentive Plan |   |   | Compensation |   |   | All Other |   |   |   |   |
|                                 |    | Cash |   |   | Awards |   |   | Awards |   |   | Compensation |   |   | Earnings |   |   | Compensation |   |   | Total |   |
| Name                                 |    | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |
| (a)                                  |    | (b) |   |   | (c) |   |   | (d) |   |   | (e) |   |   | (f) |   |   | (g) |   |   | (h) |   |
|                                 |    |
| WANG Hui                             |  $ |   | 21,960 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |
| Chi Ming YU                          |    |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |
| Kai GUI                              |    |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |

| Director Compensation |   |
|-----------------------|--------|
|                  |   | Fees |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                  |   | Earned |   |   |   |   |   |   |   |   |   |   |   | Nonqualified |   |   |   |   |   |   |   |
|                  |   | or |   |   |   |   |   |   |   |   | Non-Equity |   |   | Deferred |   |   |   |   |   |   |   |
|                  |   | Paid in |   |   | Stock |   |   | Option |   |   | Incentive Plan |   |   | Compensation |   |   | All Other |   |   |   |   |
|                  |   | Cash |   |   | Awards |   |   | Awards |   |   | Compensation |   |   | Earnings |   |   | Compensation |   |   | Total |   |
| Name                  |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |   | (US$) |   |
| (a)                   |   | (b) |   |   | (c) |   |   | (d) |   |   | (e) |   |   | (f) |   |   | (g) |   |   | (h) |   |
|                  |   |
| WANG Hui              |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |
| Chi Ming YU           |   | $ | 5,000 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |  $ | 5,000 |   |
| Kai GUI               |   | $ | 5,000 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |   | 0 |   |   |  $ | 5,000 |   |

----

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

| (1) Title of Class           | (2) Name and address of beneficial owner                                                                                 |   | (3) Amount and nature of beneficial ownership |       |   | (4) Percent of class |   |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------|------------|--------|----------------------|--------|
| Common Stock                 | WANG Hui, CEO & Director                                                                                             |   |                                          | 22,153,540 |   |                 |   | 39.227 | % |
| Common Stock                 | Chi Ming YU, President & Director                                                                                    |   |                                          | 0          |   |                 |   | 0 | % |
|                         |                                                                                                                     |   |                                          |       |   |                 |   |   |   |
| Common Stock                 | Kai GUI, Secretary & Director                                                                                        |   |                                          | 150,000    |   |                 |   | 0.266 | % |
| Common Stock                 | Titan Technology Development, LTD., Room 1903 Hing Yip, Commercial Centre, 272 Des Voeux Road Central, Hong Kong, 718332 |   |                                          | 21,049,660 |   |                 |   | 37.273 | % |
| Common Stock                 | WU Ai Ping, Room 802, 35 Weicheng Street, Hongyun Garden, Zhongtangshi Lane, Huangpu Road, Tianhe, Guangzhou, 510655     |   |                                          | 5,000,000  |   |                 |   | 8.853 | % |
| All Officers & Directors |                                                                                                                     |   |                                          | 22,303,540 |   |                 |   | 39.493 | % |

----

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

|  2011 |   | $ | 33,400 |   |  Baker Tilly Hong Kong Limited |
|------------|--------|---|--------|--------|-------------------------------------|
|  2010 |   | $ | 33,600 |   |  Baker Tilly Hong Kong Limited |

----

----

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

|    |   |                                                                                                                                             |   | Incorporated by reference |   |     |   |   |
|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------|--------|----------|--------|--------|
| Exhibit |   | Document Description                                                                                                                             |   | Form                      |   | Date     |   | Number |   | Filed herewith |
|    |   |                                                                                                                                             |   |                      |   |     |   |   |   |   |
| 3.1     |   | Articles of Incorporation                                                                                                                        |   | SB-2                      |   | 01-16-07 |   | 3.1    |   |   |
| 3.2     |   | Bylaws                                                                                                                                           |   | SB-2                      |   | 01-16-07 |   | 3.2    |   |   |
| 4.1     |   | Specimen Stock Certificate                                                                                                                       |   | SB-2                      |   | 01-16-07 |   | 4.1    |   |   |
| 14.1    |   | Code of Ethics                                                                                                                                   |   |                      |   |     |   |   |   | X |
| 10.1    |   | Titan – ABMT Loan Agreement                                                                                                                |   |                      |   |     |   |   |   | X |
| 31.1    |   | Certification of Chief Executive Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.           |   |                      |   |     |   |   |   | X |
| 31.2    |   | Certification of Chief Financial Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.           |   |                      |   |     |   |   |   | X |
| 32.1    |   | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer) |   |                      |   |     |   |   |   | X |
| 32.2    |   | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer) |   |                      |   |     |   |   |   | X |
| 99.1    |   | Audit Committee Charter                                                                                                                          |   |                      |   |     |   |   |   | X |
| 99.2    |   | Disclosure Committee Charter                                                                                                                     |   |                      |   |     |   |   |   | X |
|    |   |                                                                                                                                             |   |                      |   |     |   |   |   | X |

----

| ADVANCED BIOMEDICAL TECHNOLOGIES, INC. |                                               |
|----------------------------------------|----------------------------------------------------|
|                                   |                                               |   |
| By:                                    | /s/ Chi Ming YU, President and Director            |   |
| By:                                    | /s/ Kai GUI, Secretary and Chief Financial Officer |   |
| By:                                    | /s/ WANG Hui, Director and Chief Executive Officer |   |
| Date:                                  | February 14, 2012                                  |   |

| By:   | /s/ Chi Ming YU                                                  |   |
|-------|------------------------------------------------------------------|--------|
| Name: | Chi Ming YU, President and Director(Principal Executive Officer) |   |
| Date: | February 14, 2012                                                |   |

| By:   | /s/ WANG Hui,                                              |   |
|-------|------------------------------------------------------------|--------|
| Name: | WANG Hui, Director and Chief Executive Officer(Controller) |   |
| Date: | February 14, 2012                                          |   |

| By:   | /s/ Kai GUI                                                                           |   |
|-------|---------------------------------------------------------------------------------------|--------|
| Name: | Kai GUI, Director, Secretary and Chief Financial Officer(Principal Financial Officer) |   |
| Date: | February 14, 2012                                                                     |   |

----